Adult Obesity — Pharmacological Interventions

Publication Date: October 20, 2022

Key Points

Key Points

  • The prevalence of obesity in the United States has increased dramatically over the past few decades from 30.5% in 1999–2000 to 41.9% in 2019–2020.
  • In adults, obesity-related complications such as cardiovascular disease, stroke, type 2 diabetes mellitus (T2DM), nonalcoholic steatohepatitis, obstructive sleep apnea, osteoarthritis, and certain types of cancer (e.g., colorectal cancer) have also increased, contributing to high morbidity and mortality.
  • Lifestyle intervention(s) has limited effectiveness and durability for most individuals.
  • Pharmacological therapies with high efficacy in achieving weight loss have seen limited use, partly due to lack of familiarity and limited insurance coverage.
  • A small number of providers are responsible for >90% of the anti-obesity medication prescriptions.

Treatment

...eatment

...In adults with obesity or overweight...


...dults with obesity or overweight w...


...with obesity or overweight with weight-related com...


.... In adults with obesity or overweight w...


...with obesity or overweight with weight-related co...


...with obesity or overweight with weight-relat...


...adults with obesity or overweight with...


...dults with obesity or overweight with weight-relat...


...In adults with body mass index (BM...


...1. Anti-obesity MedicationsHaving trouble viewing...


...Pharmacological Interventions for Adults With...